Conclusions This study defines normative data for children’s exercise capacity as measured by the MST. It provides a frame of reference for parents in discussing their child’s exercise tolerance and the modified formula is easy to use (distance travelled = 55x Age + 400m).

GP283 CLINICAL AND RADIOLOGICAL EVALUATION OF PATIENTS WITH POSTINFECTIOUS BRONCHIOLITIS OBLITERANS

1Erkan Cakir, 1Fatouma Khalif, 1Mehmet Bilgin, 1Lina Al Shadfan, 1Hakan Yazan, 3Irem Yilmaz*, 4Mustafa Atilla Nursoy. 1Department of Pediatric Pulmonology, Istanbul, Turkey; 2Bezmialem Vakif University, Faculty of Medicine, Department of Pediatric Pulmonology, Istanbul, Turkey; 3Bezmialem Vakif University, Faculty of Medicine, Department of Radiology, Istanbul, Turkey; 4Bezmialem Vakif University, Faculty of Medicine, Department of Pediatrics, Istanbul, Turkey. 10.1136/archdischild-2019-epa.342

Introduction Postinfectious bronchiolitis obliterans is characterized by persistent symptoms and signs of obstructive pulmonary disease following acute bronchial injury. It usually occurs with persistent wheezing and cough as a result of severe viral infections. The aim of this study was to investigate the socio-demographic characteristics, treatment status, and clinical response of our cases of postinfectious bronchiolitis obliterans.

Methods The records of 102 patients with postinfectious bronchiolitis obliterans who were followed-up in our clinic were retrospectively reviewed. Sociodemographic characteristics, treatments, pre-treatment and post-treatment complaints, pulmonary function tests, clinical status, radiological changes were evaluated.

Results 68.6% (n = 70) of our patients were male. The mean age of the patients at the time of the study was 88.8 ± 53.5 months, and the age of diagnosis was 34.3 ± 36.4 months. The mean period from the first complaints to the date of diagnosis was 22.8 ± 33.8 months. 59% (57) of the patients had a history of smoking in one of their parents. In 62.7% of the cases, the first lower respiratory tract infection was bronchopneumonia and 36.3% was in the acute bronchiolitis. Before the diagnosis, 35 patients had intensive care hospitalization (34.3%). Persistent cough (90.2%), wheezing (96.1%), shortness of breath (91.2%) and purulent cough (75%) were the most frequent findings. When treatments of the patients were evaluated; inhaled corticosteroids were 92.2%, 6 months azithromycin 69.6%, 6 months oral steroid 61.8%. 11 patients (10.8%) needed oxygen and 10 patients (9.8%) required Bilevel Positive Airway Pressure (BPAP) support. Before and after treatment of 49 patients, lung CTs were evaluated by radiologist and modified Bhalla scores were calculated. Pre-treatment mosaism and peribronchial thickening were detected in all patients. There were bronchietasis 67.3%, atelectasis 91.8%, hyperinflation 81.6%, air trapping 98% of patients. Post-treatment radiological evaluation revealed mosaism 93.9%, peribronchial thickening 100%, bronchiectasis 51%, atelectasis 65.3%, hyperinflation 69.4%, air trapping 87.8%. The mean Bhalla score was 9.1 ± 4.1 before the treatment and it was found to be 6.8 ± 4.6 after treatment.

Discussion and Conclusion Postinfectious bronchiolitis obliterans is a rare condition with obstruction findings. It occurs as a result of immune mechanisms after severe lung infection, especially at a young age. In this study, we aimed to present sociodemographic characteristics, clinical features and especially response to long-term steroid and azithromycin treatment in patients with bronchiolitis obliterans.

GP284 THE EFFECTS OF IVACAFTOR ON PANCREATIC FUNCTION IN PAEDIATRIC PATIENTS WITH CYSTIC FIBROSIS GATING MUTATIONS

Joshua Emery*, David Mullane, Muireann Ni Chronin. University College Cork, Cork, Ireland

10.1136/archdischild-2019-epa.343

Objectives To examine the effects of Ivacaftor on growth and pancreatic function in patients attending the Paediatric Cystic Fibrosis (CF) Centre at Cork University Hospital.

Methods A retrospective, convenience sampled cohort analysis was conducted in patients aged 2 to 17 with genetically confirmed CF (N=28, 15 male, 13 female). Subjects who received Icaftor over a 1 year period had an oral dose of either 75 or 150 mg twice daily depending on weight. Patients were excluded if concurrently taking Lumacaftor. The primary end points were estimated mean change from baseline through one year in pancreatic lipase (Creon) consumption per day and body mass index (BMI). Secondary end points included the changes in mean percent of predicted forced exhaled volume Positive Airway Pressure (BPAP) support. Before and after treatment of 49 patients, lung CTs were evaluated by radiologist and modified Bhalla scores were calculated. Pre-treatment mosaism and peribronchial thickening were detected in all patients. There were bronchietasis 67.3%, atelectasis 91.8%, hyperinflation 81.6%, air trapping 98% of patients. Post-treatment radiological evaluation revealed mosaism 93.9%, peribronchial thickening 100%, bronchiectasis 51%, atelectasis 65.3%, hyperinflation 69.4%, air trapping 87.8%. The mean Bhalla score was 9.1 ± 4.1 before the treatment and it was found to be 6.8 ± 4.6 after treatment.

Discussion and Conclusion Postinfectious bronchiolitis obliterans is a rare condition with obstruction findings. It occurs as a result of immune mechanisms after severe lung infection, especially at a young age. In this study, we aimed to present sociodemographic characteristics, clinical features and especially response to long-term steroid and azithromycin treatment in patients with bronchiolitis obliterans.
Introduction Cystic Fibrosis transmembrane conductance regulator (CFTR) modulator therapies are utilised to correct the malfunctioning protein made by the CFTR gene thus producing significant improvement in lung function. However, worsening liver function is described as a potentially serious side effect by modulator suppliers.

ORKAMBI and IVACAFTOR are licensed for the treatment of cystic fibrosis (CF) in patients greater than 6 years who are homozygous for the F508del-CFTR mutation. We set out to identify changes to liver function and pathology after initiation of modulator therapy in a retrospective study of all CFLD patients.

Methodology We reviewed the liver function tests and liver ultrasound results on all patients with CFLD. We recorded anonymised test results for ALT, AST, Alk Phos, GGT and bilirubin from birth. We reviewed patient files and recorded medication histories. We mapped changes in medication against chronological liver function tests and identified trends of improving or worsening results.

Results Ninety-eight children with Cystic Fibrosis attend Tallaght. Thirteen have CFLD (13%) of which 54% are female. The predominant phenotype is ΔF508del/ΔF508del (9/13, 69%). ΔF508del/G551D was isolated in two children (15%), ΔF508del/V520F in one child (8%) and ΔF508del/Arg560Thr/Lys heterozygous in one child (8%). Seven children (7/13, 54%) take ORKAMBI and two (2/13, 15%) take IVACAFTOR. Four children with CFLD are currently taking modulator therapy due to their specific phenotype, age or social circumstances. We identified an improvement in liver function tests in 89% (8/9) since initiation of therapy - 86% taking ORKAMBI and 100% taking IVACAFTOR. One patient on ORKAMBI (1/7, 14%) had no improvement in liver function tests, with persistently raised GGT and AST, which began prior to modulator therapy initiation. 100% of the ORKAMBI cohort showed no deterioration in liver pathology over 18 months. 50% of the IVACAFTOR cohort demonstrated no deterioration in liver pathology over 6 years.

Conclusions and discussion We identified an improvement in liver function tests in 89% of children with CFLD since the commencement of modulator therapy. Limitations include the small sample size and variance in time taking modulator therapy (from 6 months to six years). Further study would be helpful to reconcile the variance between supplier side effect warnings and these results.

Abstracts

GP285 THE EFFECT OF MODULATOR THERAPY ON LIVER FUNCTION IN PATIENTS WITH CYSTIC FIBROSIS-RELATED LIVER DISEASE (CFLD)

Sharon Dempsey*, John Travers, Gerardine Leer, Geraldine Connell, Shona Quinn, Peter Grealish, Basil Elnazir. Children’s Hospital Ireland, Tallaght, Dublin, Ireland.

Introduction Cystic Fibrosis transmembrane conductance regulator (CFTR) modulator therapies are utilised to correct the malfunctioning protein made by the CFTR gene thus producing significant improvement in lung function. However, worsening liver function is described as a potentially serious side effect by modulator suppliers.

ORKAMBI and IVACAFTOR are licensed for the treatment of cystic fibrosis (CF) in patients greater than 6 years who are homozygous for the F508del-CFTR mutation. We set out to identify changes to liver function and pathology after initiation of modulator therapy in a retrospective study of all CFLD patients.

Methodology We reviewed the liver function tests and liver ultrasound results on all patients with CFLD. We recorded anonymised test results for ALT, AST, Alk Phos, GGT and bilirubin from birth. We reviewed patient files and recorded medication histories. We mapped changes in medication against chronological liver function tests and identified trends of improving or worsening results.

Results Ninety-eight children with Cystic Fibrosis attend Tallaght. Thirteen have CFLD (13%) of which 54% are female. The predominant phenotype is ΔF508del/ΔF508del (9/13, 69%). ΔF508del/G551D was isolated in two children (15%), ΔF508del/V520F in one child (8%) and ΔF508del/Arg560Thr/Lys heterozygous in one child (8%). Seven children (7/13, 54%) take ORKAMBI and two (2/13, 15%) take IVACAFTOR. Four children with CFLD are currently taking modulator therapy due to their specific phenotype, age or social circumstances. We identified an improvement in liver function tests in 89% (8/9) since initiation of therapy - 86% taking ORKAMBI and 100% taking IVACAFTOR. One patient on ORKAMBI (1/7, 14%) had no improvement in liver function tests, with persistently raised GGT and AST, which began prior to modulator therapy initiation. 100% of the ORKAMBI cohort showed no deterioration in liver pathology over 18 months. 50% of the IVACAFTOR cohort demonstrated no deterioration in liver pathology over 6 years.

Conclusions and discussion We identified an improvement in liver function tests in 89% of children with CFLD since the commencement of modulator therapy. Limitations include the small sample size and variance in time taking modulator therapy (from 6 months to six years). Further study would be helpful to reconcile the variance between supplier side effect warnings and these results.

Background Urinary tract infections (UTI) in Children can cause serious morbidity as well as Scarring of kidneys leading to renal impairment. To manage UTI in children and avoid the bad outcome, there are different guidelines for close follow up and management of these children. There were new Irish guidelines set up in 2017 regarding imaging of these children which suggested Renal ultrasound (US) at admission of clinically well children with UTI followed by the Renal US after 6 months instead of DMSA if the initial US is normal.

Method We gathered the data of all sick children under 16 years of age from January 2014-Dec 2016, who were diagnosed with Culture proven UTI and had Renal US at admission and DMSA or Renal US at follow up. We identified 70 (39 male- 55.7%, 31 females-44.3%) cases who had all the data available on Microbiology, Radiology and medical notes, and excluded all those who were either out of catchment area, who lost follow up appointments, or whose report was not traced properly. In 70 children admitted there 32 (45.7%) who had repeat US along with DMSA. The reports were verified by Expert Pediatric Radiologist.

Results We found 62 (88.5%) normal initial US (Normal parenchyma), who had normal DMSA and repeat US (24 cases). There were 8 (11.5%) children who had abnormal initial US (parenchymal changes), which were confirmed by DMSA and repeat US (8 cases).

Conclusion Renal US could be a potential alternative of DMSA in children with UTI if the initial US has been reported normal if the scans are reported by Pediatric radiologist/Special interest in pediatric radiology. The renal US is cost and time effective, and in this way, we can avoid extra costs, day admissions and family anxiety related to the procedure.